Human Longevity Inc. and AMRA Partner to Provide Advanced Body Composition Profiling to HLI’s Health Nucleus Clients
News
9 January 2018

Human Longevity Inc. and AMRA Partner to Provide Advanced Body Composition Profiling to HLI’s Health Nucleus Clients

Linköping, Sweden and San Diego, USA [January 9, 2018] AMRA, the international leader in body composition analysis, and Human Longevity, Inc. (HLI), the genomics-powered health intelligence company, have announced a new agreement that will see AMRA’s body composition profiling added to HLI’s premier health assessment, the Health Nucleus experience.

The Health Nucleus integrates genomics, metabolic profiling and other clinical testing with advanced whole body and brain magnetic resonance imaging (MRI), which now includes the body composition profiling provided by AMRA. This integrated, whole-body experience empowers patients to take control of their own health by proactively planning to stay ahead of aging and illness.

AMRA’s mission is to establish a new global standard in body composition assessment and to confront global health challenges by enhancing the evidence base needed to predict and prevent disease – a precise, cost-effective way to understand our bodies far beyond what is commonly used today. AMRA is the first company in the world to transform images from a 6-minute whole body MRI into 3D-volumetric fat and muscle measurements, while enabling market-leading accuracy and precision when assessing fat and muscle volume and distribution, as well as metabolic status.

“The HLI Health Nucleus has been positively impacting people’s lives for three years by giving them and their physicians access to some of the most comprehensive health testing available today,” said J. Craig Venter, PH.D., HLI’s CEO. “While we have been piloting AMRA’s body composition profiling for over a year, we are excited to now offer their unique modality to all our Health Nucleus clients. We believe this will provide an additional and valuable layer of powerful insight into a person’s metabolic status.”

Tommy Johansson, Chief Executive Officer of AMRA, commented, “This is an exciting day for AMRA, as we take a significant step forward in our journey to advance the cause of precision medicine and preventive care. Through our partnership with HLI, individuals will now be able to access our technology for the first time outside of medical research. We hope that our body composition profiling, combined with HLI’s cutting-edge digital health assessments, will set the standard for the future of personalized healthcare.”

 

-ENDS-

 

About Human Longevity INC

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business focus includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com.

 

HLI Contact:

Heather Kowalski

Head of Corporate Communications and Marketing

hkowalski@humanlongevity.com

 

About AMRA

AMRA is an international digital health company and the first in the world to transform images from a rapid, 6-minute whole body MRI scan into precise, 3D-volumetric fat and muscle measurements.

AMRA’s cloud-based analysis service – AMRA® Profiler Research – offers precise, automated insights that have far-reaching implications for the pharmaceutical industry, academic R&D and, soon, clinical practice. Headquartered in Sweden, AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden. For more information, visit: www.amramedical.com

 

Contact:

Chelsea Ranger

SVP Business Development

chelsea.ranger@amramedical.com

Relevant Information